SK283930B6 - Farmaceutický aerosólový prostriedok a farmaceutický výrobok s jeho obsahom - Google Patents
Farmaceutický aerosólový prostriedok a farmaceutický výrobok s jeho obsahom Download PDFInfo
- Publication number
- SK283930B6 SK283930B6 SK1576-99A SK157699A SK283930B6 SK 283930 B6 SK283930 B6 SK 283930B6 SK 157699 A SK157699 A SK 157699A SK 283930 B6 SK283930 B6 SK 283930B6
- Authority
- SK
- Slovakia
- Prior art keywords
- pharmaceutical
- ethanol
- aerosol formulation
- valve stem
- ciclesonide
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 64
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims abstract description 33
- 229960003728 ciclesonide Drugs 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000003380 propellant Substances 0.000 claims abstract description 19
- 238000009472 formulation Methods 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 7
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008249 pharmaceutical aerosol Substances 0.000 claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 8
- -1 isobutanoyl Chemical group 0.000 claims description 8
- 238000005086 pumping Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 229940127557 pharmaceutical product Drugs 0.000 claims 7
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- SEKYBDYVXDAYPY-ILNISADRSA-N (8s,9s,10r,11s,13s,14s,16r,17s)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical group O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 SEKYBDYVXDAYPY-ILNISADRSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229920000459 Nitrile rubber Polymers 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Materials For Medical Uses (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
Description
mg/ml | |
ciclesonid | 1,000 |
etanol (8 %) | 102,160 |
P227 | 586,920 |
P 134a | 586,920 |
11277,000 |
mg/ml | |
ciclesonid | 1,000 |
etanol (5 %) | 67,800 |
P227 | 1287,200 |
1356,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (5 %) | 67,800 |
P227 | 1283,200 |
1356,000 |
mg/ml | |
ciclesonid | 1,000 |
etanol (20 %) | 244,800 |
P227 | 978,200 |
1224,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (20 %) | 244,800 |
P227 | 974,200 |
1224,000 |
mg/ml | |
ciclesonid | 1,000 |
etanol (7 %) | 82,740 |
P 134a | 1098,260 |
1182,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (7 %) | 82,740 |
P 134a | 1094,260 |
1182,000 |
mg/ml | |
ciclesonid | 1,000 |
etanol (20 %) | 220,800 |
PI 34a | 882,200 |
1104,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (8 %) | 220,800 |
P 134a | 878,200 |
1104,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (8 %) | 102,160 |
P227 | 584,920 |
P 134a | 584,920 |
11277,920 |
mg/ml | |
ciclesonid | 1,000 |
etanol (12 %) | 126,500 |
P227 | 568,750 |
P 134a | 568,750 |
1265,000 |
mg/ml | |
ciclesonid | 5,000 |
etanol (120i) | 126,500 |
P227 | 566,750 |
P 134a | 566,750 |
1151,000 |
mg/ml | |
ciclesonid | 1,000 |
etanol | 94,800 |
P 134a | 1090,200 |
1186,000 |
mg/ml | |
ciclesonid | 2,000 |
etanol | 94,7200 |
P 134a | 1089,280 |
1186,000 |
mg/ml | |
ciclesonid | 4,000 |
etanol | 94,5600 |
PI 34a | 1087,440 |
1186,000 |
mg/ml | |
ciclesonid | 4,000 |
kyselina olejová | 0,237 |
etanol | 94,541 |
PI 34a | 1087,222 |
1186,000 |
Claims (19)
- PATENTOVÉ NÁROKY1. Farmaceutický aerosólový prostriedok, vyznačujúci sa tým, že zahrnuje terapeuticky účinné množstvo zlúčeniny všeobecného vzorca (I)CUi-O-'R2 kde:R1 znamená 1-butyl, 2-butyl, cyklohexyl alebo fenyl,R2 znamená acetyl alebo izobutanoyl a propelent vybraný zo skupiny 1,1,1,2-tetrafluóretán, 1,1,1,2,3,3,3-heptafluórpropán a ich zmesi a etanol v množstve schopnom rozpustiť zlúčeninu všeobecného vzorca (I).
- 2. Farmaceutický aerosólový prostriedok podľa nároku 1, vyznačujúci sa tým, že obsahuje povrchovo aktívne látky.
- 3. Farmaceutický aerosólový prostriedok podľa nároku 1 alebo 2, vyznačujúci sa tým, že zlúčeninou všeobecného vzorca (I) je ciclesonid.
- 4. Farmaceutický aerosólový prostriedok podľa nároku 1 alebo 2, vyznačujúci sa tým, že obsahuje od 3 do 25 % hmotnostných etanolu.
- 5. Farmaceutický aerosólový prostriedok podľa nároku4, vyznačujúci sa tým, že obsahuje od 5 do 25 % hmotnostných etanolu.
- 6. Farmaceutický aerosólový prostriedok podľa nároku5, vyznačujúci sa tým, že obsahuje 7 až 12 % hmotnostných etanolu.
- 7. Farmaceutický aerosólový prostriedok podľa nároku6, vyznačujúci sa tým, že obsahuje 8 % hmotnostných etanolu.
- 8. Farmaceutický aerosólový prostriedok podľa nároku3, vyznačujúci sa tým, že obsahuje od 1 do 8 mg/ml ciclesonidu.
- 9. Farmaceutický aerosólový prostriedok podľa nároku 1 alebo 2, vyznačujúci sa tým, že prope1 entom j e 1,1,1,2-tetrafluóretán.
- 10. Farmaceutický aerosólový prostriedok podľa nároku 1 alebo 2, vyznačujúci sa tým, že propelentomje 1,1,1,2,3,3,3-heptafluóropropán.
- 11. Farmaceutický aerosólový prostriedok podľa nároku 9, vyznačujúci sa tým, že pozostáva z ciclesonidu v koncentrácii 1 až 5 mg/ml v zmesi etanolu a 1,1,1,2-tetrafluóretánu v hmotnostnom pomere 8 : 92.
- 12. Farmaceutický výrobok, vyznačujúci sa tým, že pozostáva z aerosólovej nádobky vybave nej ventilom a farmaceutického prostriedku podľa nároku 1 alebo 2.
- 13. Farmaceutický výrobok podľa nároku 12, vyznačujúci sa tým, že ventilom je dávkovací ventil.
- 14. Farmaceutický výrobok podľa nároku 13, vyznačujúci sa tým, že dávkovací ventil pozostáva z:ochranného krúžku, ktorý má obrubu a obrubové tesnenie na spojenie s aerosólovou nádobkou a otvor;dávkovacieho zásobníka, ktorý má steny vymedzujúce exteriér, vnútornú dávkovaciu dutinu, vstupný otvor, vstupný koniec a výstupný koniec;podlhovastej stopky ventilu, ktorá má čerpací kanál, čerpací koniec, vyprázdňovací koniec a vyprázdňovaci otvor;pričom výstupný koniec dávkovacieho zásobníka je v tesniacom spojení s ochranným krúžkom, vyprázdňovací koniec stopky ventilu prechádza otvorom v ochrannom krúžku a výstupným koncom dávkovacieho zásobníka a je v kízavom tesniacom spojení s ochranným krúžkom;pričom čerpací koniec stopky ventilu prechádza cez vstupný otvor dávkovacieho zásobníka a je s ním v kĺzavom spojení, a fľašový vyprázdňovač obkolesuje dávkovací zásobník a čerpací koniec podlhovastej stopky ventilu, a definuje prechod medzi dávkovacím zásobníkom a fľašovým vyprázdňovačom, čím umožňuje styk medzi vstupným otvorom dávkovacieho zásobníka a aerosólovou nádobkou;pričom ventilová stopka je pohyblivá medzi natiahnutou zavretou polohou, pričom čerpací kanál ventilovej stopky umožňuje otvorený styk cez vstupný otvor, medzi interiérom a exteriérom dávkovacej dutiny, a pričom výstupný koniec dávkovacieho zásobníka je zavretý, a stlačenou otvorenou polohou, pričom vstupný otvor dávkovacieho zásobníka je v tesniacom spojení s čerpacím koncom ventilovej stopky a vyprázdňovací otvor umožňuje otvorený styk medzi interiérom a exteriérom dávkovacej dutiny.
- 15. Farmaceutický výrobok podľa nároku 14, vyznačujúci sa tým, že zahŕňa adaptér, ktorý má telo na pripojenie k aerosólovej nádobke, nadstavec na prispôsobenie sa vyprázdňovaciemu koncu stopky ventilu a nátrubok.
- 16. Farmaceutický výrobok podľa nároku 15, vyznačujúci sa tým, že nadstavec má výstupný otvor namierený oproti nátrubku a výstupný otvor má priemer v rozpätí od 0,20 do 0,33 mm.
- 17. Farmaceutický výrobok podľa nároku 16, vyznačujúci sa tým, že výstupný otvor má priemer približne 0,28 mm.
- 18. Farmaceutický výrobok podľa nároku 17, vyznačujúci sa tým, že výstupný otvor má dĺžku dýzy v rozpätí od 0,30 do 0,60 mm.
- 19. Farmaceutický výrobok podľa nároku 18, vyznačujúci sa tým, že výstupný otvor má dĺžku dýzy 0,50 mm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9710496.2A GB9710496D0 (en) | 1997-05-21 | 1997-05-21 | Medicinal aerosol products |
GBGB9803990.2A GB9803990D0 (en) | 1998-02-25 | 1998-02-25 | Medicinal aerosol products |
PCT/US1998/010155 WO1998052542A1 (en) | 1997-05-21 | 1998-05-18 | Medicinal aerosol products |
Publications (2)
Publication Number | Publication Date |
---|---|
SK157699A3 SK157699A3 (en) | 2000-05-16 |
SK283930B6 true SK283930B6 (sk) | 2004-05-04 |
Family
ID=26311564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1576-99A SK283930B6 (sk) | 1997-05-21 | 1998-05-18 | Farmaceutický aerosólový prostriedok a farmaceutický výrobok s jeho obsahom |
Country Status (28)
Country | Link |
---|---|
US (1) | US6120752A (sk) |
EP (1) | EP0983058B1 (sk) |
JP (4) | JP2001526685A (sk) |
KR (1) | KR100527643B1 (sk) |
CN (1) | CN1149073C (sk) |
AT (1) | ATE245966T1 (sk) |
AU (1) | AU726835B2 (sk) |
BG (1) | BG64268B1 (sk) |
BR (1) | BR9809448A (sk) |
CA (1) | CA2290521C (sk) |
CZ (1) | CZ298253B6 (sk) |
DE (1) | DE69816811T2 (sk) |
DK (1) | DK0983058T3 (sk) |
EA (1) | EA002381B1 (sk) |
ES (1) | ES2205491T3 (sk) |
HK (1) | HK1027027A1 (sk) |
HU (1) | HU226694B1 (sk) |
IL (1) | IL132738A (sk) |
ME (1) | ME01631B (sk) |
NO (2) | NO327716B1 (sk) |
NZ (1) | NZ500874A (sk) |
PL (1) | PL191523B1 (sk) |
PT (1) | PT983058E (sk) |
RS (1) | RS49628B (sk) |
SK (1) | SK283930B6 (sk) |
TR (1) | TR199902863T2 (sk) |
UA (1) | UA58551C2 (sk) |
WO (1) | WO1998052542A1 (sk) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
US6315985B1 (en) | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
AR026072A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
GB0002798D0 (en) * | 2000-02-09 | 2000-03-29 | Glaxo Group Ltd | Actuator nozzle for metered dose inhaler |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
GB0207899D0 (en) * | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and cielesonide aerosol formulations |
WO2004033478A2 (en) * | 2002-10-08 | 2004-04-22 | Sepracor Inc. | Fatty acid modified forms of glucocorticoids and their use as anti-inflammatory |
KR101235583B1 (ko) * | 2002-10-25 | 2013-02-22 | 허니웰 인터내셔널 인코포레이티드 | 플루오린 치환된 올레핀을 함유하는 조성물 |
ATE405275T1 (de) * | 2002-12-12 | 2008-09-15 | Nycomed Gmbh | Kombinationsarzneimittel aus r,r-formoterol und ciclesonide |
MY143936A (en) * | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
WO2004103379A1 (en) * | 2003-05-22 | 2004-12-02 | Altana Pharma Ag | Salmeterol and ciclesonide combination |
JP2006527237A (ja) * | 2003-06-13 | 2006-11-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ホルモテロールと及びシクレソニドの組合せ物 |
EP1670482B2 (en) * | 2003-09-16 | 2022-06-29 | Covis Pharma B.V. | Use of ciclesonide for the treatment of respiratory diseases |
GB2406283B (en) | 2003-09-24 | 2006-04-05 | Altana Pharma Ag | Compliance monitor and method |
US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
WO2005065185A2 (en) * | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
EP1740188A1 (en) * | 2004-04-20 | 2007-01-10 | Altana Pharma AG | Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
JP2008512428A (ja) * | 2004-09-10 | 2008-04-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクレソニドとSykインヒビターとの組合せ物並びにその使用方法 |
JP2008546634A (ja) * | 2005-03-16 | 2008-12-25 | ハネウェル・インターナショナル・インコーポレーテッド | 医薬送達製剤、デバイス及び方法 |
WO2007068007A1 (en) * | 2005-12-07 | 2007-06-14 | Harm Benjamin Steyn | Use of a disinfectant for treating respiratory tract infections |
PT2425820E (pt) | 2007-02-11 | 2015-08-04 | Map Pharmaceuticals Inc | Método de administração terapêutica de dhe para permitir o rápido alívio das enxaquecas ao mesmo tempo que minimiza o perfil de efeitos secundários |
US20100120737A1 (en) * | 2008-11-10 | 2010-05-13 | Martin Feth | Amorphous ciclesonide |
TWI465459B (zh) * | 2009-03-09 | 2014-12-21 | Mikasa Seiyaku Co Ltd | 類固醇化合物 |
WO2011135585A2 (en) | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Aqueous pharmaceutical solution of ciclesonide |
KR20180028563A (ko) * | 2010-10-12 | 2018-03-16 | 시플라 리미티드 | 약학 조성물 |
CA2844944A1 (en) | 2011-08-18 | 2013-02-21 | Takeda Gmbh | Pharmaceutical aerosol product for administration by oral or nasal inhalation |
CN102335132A (zh) * | 2011-10-12 | 2012-02-01 | 中山大学 | 一种细辛脑吸入气雾剂及其制备方法 |
EP2809780B1 (en) | 2012-02-01 | 2018-05-02 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2077229B (en) * | 1980-05-16 | 1983-08-03 | Neotechnic Eng Ltd | Valve assembly for a pressurized aerosoldispensing container |
GB8824804D0 (en) * | 1988-10-22 | 1988-11-30 | Fisons Plc | Device |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8900267D0 (en) * | 1989-01-06 | 1989-03-08 | Riker Laboratories Inc | Narcotic analgesic formulations and apparatus containing same |
GB8921222D0 (en) * | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
IE67185B1 (en) * | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
DE4003272A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
WO1991014422A1 (en) * | 1990-03-23 | 1991-10-03 | Minnesota Mining And Manufacturing Company | The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
GR1001529B (el) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
CA2094266C (en) * | 1990-10-18 | 1999-06-01 | Robert K. Schultz | Aerosol formulations of beclomethasone-17,21-dipropionate |
US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
US5474758A (en) * | 1993-07-28 | 1995-12-12 | Minnesota Mining And Manufacturing Company | Seals for use in an aerosol delivery device |
PT735884E (pt) * | 1993-12-20 | 2000-09-29 | Minnesota Mining & Mfg | Formulacoes de aerossol de flunisolida |
DE19541689A1 (de) * | 1994-11-14 | 1996-05-15 | Byk Gulden Lomberg Chem Fab | Kombinationsarzneimittel |
US5653961A (en) * | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
CA2217954C (en) * | 1995-04-14 | 2005-02-15 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
ATE219934T1 (de) * | 1995-04-14 | 2002-07-15 | Smithkline Beecham Corp | Dosierinhalator für albuterol |
HUP9800641A3 (en) * | 1995-04-14 | 2001-04-28 | Glaxo Wellcome Inc Res Triangl | Metered dose inhaler for beclomethasone dipropionate |
-
1998
- 1998-05-13 US US09/076,958 patent/US6120752A/en not_active Expired - Lifetime
- 1998-05-18 DK DK98922409T patent/DK0983058T3/da active
- 1998-05-18 PL PL336885A patent/PL191523B1/pl unknown
- 1998-05-18 EA EA199900991A patent/EA002381B1/ru not_active IP Right Cessation
- 1998-05-18 CN CNB98805261XA patent/CN1149073C/zh not_active Expired - Lifetime
- 1998-05-18 ES ES98922409T patent/ES2205491T3/es not_active Expired - Lifetime
- 1998-05-18 JP JP55049498A patent/JP2001526685A/ja active Pending
- 1998-05-18 CA CA002290521A patent/CA2290521C/en not_active Expired - Lifetime
- 1998-05-18 PT PT98922409T patent/PT983058E/pt unknown
- 1998-05-18 TR TR1999/02863T patent/TR199902863T2/xx unknown
- 1998-05-18 KR KR10-1999-7010773A patent/KR100527643B1/ko active IP Right Grant
- 1998-05-18 AT AT98922409T patent/ATE245966T1/de active
- 1998-05-18 DE DE69816811T patent/DE69816811T2/de not_active Expired - Lifetime
- 1998-05-18 RS YUP-598/99A patent/RS49628B/sr unknown
- 1998-05-18 UA UA99116244A patent/UA58551C2/uk unknown
- 1998-05-18 IL IL13273898A patent/IL132738A/en not_active IP Right Cessation
- 1998-05-18 BR BR9809448-3A patent/BR9809448A/pt not_active Application Discontinuation
- 1998-05-18 ME MEP-1999-598A patent/ME01631B/me unknown
- 1998-05-18 HU HU0002691A patent/HU226694B1/hu active Protection Beyond IP Right Term
- 1998-05-18 EP EP98922409A patent/EP0983058B1/en not_active Expired - Lifetime
- 1998-05-18 AU AU74962/98A patent/AU726835B2/en not_active Expired
- 1998-05-18 WO PCT/US1998/010155 patent/WO1998052542A1/en active IP Right Grant
- 1998-05-18 SK SK1576-99A patent/SK283930B6/sk not_active IP Right Cessation
- 1998-05-18 NZ NZ500874A patent/NZ500874A/en not_active IP Right Cessation
- 1998-05-18 CZ CZ0412499A patent/CZ298253B6/cs not_active IP Right Cessation
-
1999
- 1999-11-18 NO NO995667A patent/NO327716B1/no not_active IP Right Cessation
- 1999-11-19 BG BG103902A patent/BG64268B1/bg unknown
-
2000
- 2000-08-30 HK HK00105446A patent/HK1027027A1/xx not_active IP Right Cessation
-
2009
- 2009-10-26 NO NO2009024C patent/NO2009024I2/no unknown
-
2010
- 2010-12-03 JP JP2010270854A patent/JP2011102301A/ja not_active Withdrawn
-
2014
- 2014-09-16 JP JP2014187710A patent/JP6087882B2/ja not_active Expired - Lifetime
-
2016
- 2016-05-19 JP JP2016100499A patent/JP6178459B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK283930B6 (sk) | Farmaceutický aerosólový prostriedok a farmaceutický výrobok s jeho obsahom | |
US20130143849A1 (en) | Use of ciclesonide for the treatment of respiratory diseases | |
US6264923B1 (en) | Medicinal aerosol formulation of ciclesonide and related compounds | |
ITRM20000491A1 (it) | Formulazione farmaceutica di propionato di fluticasone. | |
RU2650175C2 (ru) | Фармацевтические аэрозольные препараты формотерола и беклометазона дипропионата | |
US11992556B2 (en) | Pharmaceutical aerosol product for administration by oral or nasal inhalation | |
JP2007533706A (ja) | 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用 | |
US20060127323A1 (en) | Formoterol and ciclesonide combination | |
MXPA99010646A (es) | Productos medicinales en aerosol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC4A | Change of owner's name |
Owner name: TAKEDA GMBH, KONSTANZ, DE Effective date: 20130725 |
|
PC4A | Assignment and transfer of rights |
Owner name: NYCOMED GERMANY HOLDING GMBH, KONSTANZ, DE Free format text: FORMER OWNER: NYCOMED ASSET MANAGEMENT GMBH, KONSTANZ, DE Effective date: 20151210 Owner name: NYCOMED ASSET MANAGEMENT GMBH, KONSTANZ, DE Free format text: FORMER OWNER: TAKEDA GMBH, KONSTANZ, DE Effective date: 20151210 |
|
TC4A | Change of owner's name |
Owner name: TAKEDA GMBH, KONSTANZ, DE Effective date: 20151210 |
|
MK4A | Patent expired |
Expiry date: 20180518 |
|
SPCT | Transfer of rights of an spc |
Free format text: OWNER(S): ASTRAZENECA AB, SOEDERTAELJE, SE; FORMER OWNER: TAKEDA GMBH, KONSTANZ, DE Spc suppl protection certif: 36 5-2005 Effective date: 20190131 |
|
SPCE | Expiry of an spc |
Spc suppl protection certif: 36 5-2005 Effective date: 20190416 |